Tocilizumab, a monoclonal antibody that blocks both membrane-bound and circulating IL6R, has anti-inflammatory actions that extend beyond reductions in C-reactive protein and fibrinogen concentrations.8, 9 Tocilizumab is licensed for treatment of rheumatoid arthritis10, 11, 12 and has been shown to reduce articular inflammation and promote disease remission.13, 14 However, adequately powered, long-term trials of tocilizumab on risk of cardiovascular disease have not yet been undertaken. The gene discussed is CRP; the disease is cardiovascular disorder.